Interleukin-2-induced increases in climbing behavior: Inhibition by dopamine D-1 and D-2 receptor antagonists

Brain Research

Volumn 944, Issue 1-2, 2002, Pages 157-164

  Zalcman, Steven S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Dopamine D 1 receptor; Dopamine D 2 receptor; NMDA; SCH 23390; Schizophrenia; Sulpiride

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SULPIRIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CLIMBING; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; LIMBIC CORTEX; MALE; MENTAL DISEASE; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; INTERLEUKIN-2; MALE; MENTAL DISORDERS; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; NEURAL PATHWAYS; NEURONS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; UP-REGULATION;

EID: 0037135165     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02740-3     Document Type: Article

References (61)

1. Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells
2. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation
3. Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: Interaction with the cholinergic system
4. Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain
5. The interleukins-1α, -1β and -2 do not acutely disrupt the murine blood-brain barrier
6. Effects of peripheral cytokine injections on multiple unit activity in the anterior hypothalamic area of the mouse
7. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration
8. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation
9. An assessment of the effects of central interleukin-1β, -2, -6 and tumor necrosis factor-α administration on some behavioral, neurochemical, endocrine and immune parameters in the rat
10. Spontaneous climbing behavior of mice, its measurement and dopaminergic involvement
11. Cytokines and sickness behavior
12. Differential ability of selective and nonselective dopamine agonist to induce climbing in the rat indicates involvement of both D-1 and D-2 receptors in this behaviour
13. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
14. Behavioural and EcOG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats is antagonized by naloxone
15. Interleukin-2 transcripts in human and rodent brains: Possible expression by astrocytes
16. Differential central nervous system responses following single and multiple recombinant IL-2 infusions
17. Effects of adrenalectomy on responses mediated by dopamine D-1 and D-2 receptors
18. Toxicity of interferon and interleukins
19. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists
20. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex
21. Modulation of hippocampal acetylcholine release: A potent central action of interleukin-2
22. Neurotoxic consequences of central long-term administration of interleukin-2 in rats
23. Anterior pituitary hormone control by interleukin-2
24. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics
25. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety
26. Central monoamine activity following acute and repeated systemic interleukin-2 administration
27. A role for interleukin-2 in the regulation of striatal dopaminergic function
28. Inhibition by noncompetitive NMDA receptor antagonists of apomorphine-induced climbing behavior in mice
29. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
30. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioural responses: A quantitative phenomenological study in rats
31. Increases in CSF levels of interleukin-2: Effects of recurrence of psychosis and medication status
32. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain
33. Production of climbing behavior in mice requires both D1 and D2 receptor activation
34. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
35. Paroxetine for the prevention of depression induced by high-dose interferon-α
36. Behavioral and electrocortical spectrum power effects after microinfusion of lymphokines in several areas of the rat brain
37. Tumour necrosis factor-α and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat
38. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2
39. Impaired learning and memory and altered hippocampal neurodevelopment resulting form interleukin-2 gene deletion
40. Molecular cloning of a partial of a partial cDNA coding of the IL-2 receptor-β in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells
41. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behavior in rats
42. Effects of the putative D1 antagonist SCH 23390 on stereotyped behavior induced by the D2 agonist RU24213
43. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release form the amygdala and involves a nitric oxide-mediated signaling mechanism: Comparison with the hypothalamic response
44. Serum soluble interleukin-2 receptors in neuroleptic naïve schizophrenic patients and in medicated schizophrenic subjects with and without tardive dyskinesia
45. An association between increased soluble interleukin-2 receptors and a disturbance in motor muscle force in schizophrenic patients
46. Interleukin-2 promotes survival and neurite extension of cultured neurons from fetal rat brain
47. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier
48. Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients
49. Variations of nucleus accumbens dopamine or serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment
50. The roles of IL-1, IL-6, and TNFα in the feeding responses to endotoxin and influenza virus infection in mice
51. Differential effects of direct and indirect dopamine agonists on the induction of gnawing in C57Bl/6J mice
52. Climbing and stereotyped behaviors in mice require the stimulation of D-1 dopamine receptors
53. Interleukin-2 does not cross the blood-brain barrier by a saturable transport system
54. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
55. Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons
56. Endotoxin produces a depressive-like episode in rats
57. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity
58. Cytokine-specific central monoamine alterations induced by interleukin-1, -2, and -6
59. Interleukin-2 and -6 induce behavioral-activating effects in mice
60. Bromocriptine induces climbing behaviour: Possible D-1 or D-2 dopamine receptor involvement